Background: The bcl-2 oncoprotein is suggested to be directly involved in the emergence of drug resistance by disrupting or delaying the apoptotic program and promoting tumor survival.
Background
In the treatment of leukemias, most of the chemotherapeutic agents exert their cytotoxic effect by induction of apoptosis [1, 2] . Therefore, poor response to induction therapy or persistance of residual disease responsible for following relapses may be caused by resistance of leukemic blasts to induction of apoptosis. Consequently, the regulation of apoptotic or antiapoptotic pathways is of high clinical importance regarding remission induction or overcoming of drug resistance. The cellular susceptibility to apoptosis is known to be regulated by a number of various genes including the protooncogene bcl-2. It encodes for an inner mitochondrial membrane protein which is known to suppress or delay the onset of apoptosis by stabilizing the mitochondrial transmembrane potential [3, 4] . The bcl-2 protein is expressed in both normal and malignant haematopoietic cells including leukemic blasts derived from acute myeloid leukemia (AML) [5, 6] .
In vitro evidence suggests a significant role oibcl-2 in promoting drug resistance in AML. The in vitro chemosensitivity of AML cells to cytosine-arabinoside (Ara-C), the most active agent in AML therapy, can be increased by suppressing the bcl-2 expression with antisense oligonucleotides [7] or a\\-trans retinoic acid [8] . In addition, artificial upregulation of bcl-2 expression in leukemic cells, tumor cell lines and bone marrow progenitors resulted in enhanced resistance to antineoplastic drugs and decreased myelosuppression [9] [10] [11] . The quantitation of resistance revealed a 3 logio enhancement of chemoresistance to Ara-C in 6c/-2-transfected leukemic cells [12] .
Moreover, it has been shown that AML blasts with autonomous proliferation in culture express high levels of bcl-2 and have increased resistance to chemotherapy [13, 14] . Additionally, those patients with autonomous blast growth in vitro were found to have a poor clinical response and a reduced survival [13, 15] .
There are few reports about the correlation of bcl-2 protein level and prognosis in AML, in the way that bcl-2 protein expression was associated with a significantly shorter overall survival due to poor response to chemotherapy [16, 17] . In chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphomas significant differences in clinical outcome were found based on the level of bcl-2 protein expression [18, 19] . In contrast, the relevance of bcl-2 in acute lymphoblastic leukemia (ALL) and non-haematopoietic malignancies remains unclear [20] . In ALL the expression of bcl-2 protein was found to be associated with prolonged life span of lymphoblasts and the presence of chromosomal aberrations [21, bd-2cONA
PCR product 315 bp
In order to define unequivocally the clinical significance of bcl-2 expression in AML, we studied the expression of bcl-2 mRNA and its correlation to treatment outcome, long-term prognosis and prognostic indicators like cytogenetics. The patient group was prospectively accrued and treated mainly with the same multiagent chemotherapy. The internal standard for quantitative bcl-2 PCR was constructed by PCR using a special 3'-primer. At the 3'-end of the 'normal' 3'-primer, a second primer sequence annealing 83 bp upstream of the 3'-primer site was fused. PCR carried out with this 'chimeric'-primer resulted in a product with shortened length, containing the target sequences of the 'normal' bcl-2 primers. This amplicon was cloned in a PCR vector. The plasmid served as an internal standard. (C) After P-actin normalization sample cDNA was amplifed together with different concentrations of internal standard cDNA for quantitation of bcl-2 transcripts. The normal bcl-2 primer pair revealed two different bands for each amplification. 22 ], but not with prognosis [21, 23, 24] . Moreover, in some solid tumors as soft tissue sarcomas, cervical carcinomas and malignant melanomas high bcl-2 protein expression seems even to be associated with less aggressive and low proliferative behaviour and may indicate a favorable prognosis [25] [26] [27] . To analyze blast cells for bcl-2 mRNA, heparmized bone marrow was recovered at time of diagnosis. No frozen or thawed cells have been used. After density gradient sedimentation using Ficoll-Hypaque, the samples were washed twice in phosphate-buffered saline (PBS) and used for RNA extraction.
Patients and methods

Patients and materials
The treatment schedule for all newly diagnosed AMLs included to the study consisted of induction and early consolidation courses with a combination of cytosin-arabinoside (Ara-C), etoposide and an anthracycline (daunorubicine or idarubicine). Patients with an age < 50 years received a late consolidation therapy with a high-dose Ara-C regimen, those with an age > 50 years received an intermediate-high dose Ara-C regimen. Patients with promyelocytic leukemia (AML FAB M3) received a special chemotherapy protocol including a\\-trans retinoic acid. Informed consent according to the criteria of the local ethical commission was required for participation.
RNA isolation and PCR
Total RNA was prepared according to the technique published by Chomczynski and Sacchi [29] using the RNAzol B method (Biotex, Houston, TX). After purification, the total RNA was redissolved in diethylpyrocarbonat-treated water and aliquots of 5 ug total RNA were reverse transcribed into cDNA as described [30] . All reagents were purchased from Gibco/BRL (Berlin, Germany).
Polymerase chain reaction (PCR) was performed as described previously [31, 32] and according to the instructions of the manufacturer. Oligonucleotides specific for bcl-2 mRNA annealing in the coding were synthesized as follows (bcl-2 5'-primer: 5'-CCG-CTACCGCCGCGACTTC; bcl-2 3' primer: 5'-AAACAGAGGCCG-CATGCTG). Amplifications of bcl-2 cDNA were performed with 35 cycles with the following conditions: The cycles were initiated by denaturing the DNA at 94 "C for 30 sec, followed by an annealing reaction for 30 sec at 64 °C and extending at 72 °C for 45 sec. After the last cycle, a final extension reaction at 72 °C for 7 min was performed.
To estimate the integrity and amount of cDNA, the P-actin gene was amplified as an internal control (5'-primer: 5'-AGCAAGAGAGG-CATCCTGACC: 3'-primer: S'-CTTCATGATGGAGTTGAAGGTAG). Each PCR included a negative control with ddH 2 O and a positive control with the bcl-2 expressing cell line KG1 (ATCC, Rockville. MD).
Amplification products were separated by electrophoresis on an 2% agarose gel and visualized by ethidium bromide staining. The ethidium bromide stained and photographed amplification product was visually classified in not amplified (-). weakly (+). moderately (++) and strongly (+++) amplified as described previously [30, 33] .
Quantitative PCR A competitive template serving as an internal standard for quantitation of bcl-2 mRNA was designed as previously described [30, 34] . The internal standard for bcl-2 was constructed by PCR. A 3'-primer annealing 83 bp upstream of the 3'-primer site for bcl-2 PCR was designed with the sequence of the normal primer site (as above) linked at the 5' end (bcl-2 internal standard 3'-primer 5'-AACAGAGGCCGC4rGCTG-CCGGTTCAGGTACTCAGTCAT-3'. The PCR product obtained by using this primer was cloned into pT7Blue (Novagen, Abingdon, UK). PCR amplification of this construct resulted in a 253 bp product.
After p-actin normalization sample cDNA was amplified together with 3 ul standard cDNA containing 0.04 fg/ul, 0.4 fg/ul, 4 fg/ul, 40 fg/ul, 400 fg/ul, 4,000 fg/ul, respectively. PCR conditions were the same as described above. The PCR products were separated on a 2% agarose gel and analyzed densitometrically using the Gel Doc 1,000 Video Gel Documentation System (Bio-Rad, Munich, Germany) and the Molecular Analyst Software (Bio-Rad, Munich, Germany).
In order to determine the exact amount of bcl-2 specific mRNA, the decadic logarithm of the quotient of volume of the sample and the standard was plotted against the decadic logarithm of the amount of standard RNA Linear regression analysis was performed. At the point, where the regression curve intercepted the X-axis and ratio equaled 1, the amount of standard and of the sample were identical ( Figure 2 ).
Bcl-2 protein expression by flowcytotnetry
For detection of the cytoplasmatic protein bcl-2 bone marrow cells were permeabilizied using the Fix-and-Perm-Kit (Fa. Dianova, Hamburg, Germany) as described by the manufacturer. The cells were incu- 
Results
Expression of bcl-2 mRNA in acute myeloid leukemias
Total mRNA of 156 bone marrow samples from patients with newly diagnosed AML (119 patients with de novo AML, 37 patients with antecedent MDS), as well as 42 AML patients in relapse and 21 AML patients in CR were analyzed for bcl-2 specific transcripts. The ethidium bromide stained amplification products of the bcl-2 PCR were visually classified in negative (-), weakly (+), moderately (++) and strongly (+++) amplified as described previously [30, 33] . The quantitative PCR (Figure 2 ) revealed that the (+) classified PCR products corresponded to 77 fg (±35.3) RNA for bcl-2, the (++) to 6.9 pg (±3.6) and the (+++) to 45 pg (±14.2). Not amplified PCR products were below the detection limit (< 10 fg specific RNA out of 1 ug total RNA). The bcl-2 specific mRNA contents were about 2 log 10 higher in moderately and strongly amplified products than in the others. Therefore, AMLs with no or weakly detectable bcl-2 signals and those with moderate and strong bcl-2 levels were summarized as one group each for survival analyses.
In 105 of 119 de novo AML patients (88%) and 26 of 37 (70%) in patients with antecedent MDS bcl-2 specific transcripts were detectable by RT-PCR (P < 0.02).
As shown in Table 1 , the intensity of the bcl-2 expression did not differ significantly between the various FAB subtypes, with the exception of monocytic leukemias (FAB M4 and M5). In those AMLs the percentage of high-expressing patients was significantly lower than in other subtypes (P -0.013).
The rate of high expression of bcl-2 mRNA in AML patients in CR was significantly lower compared to de novo AML cases (P = 0.015) or to AMLs in relapse (P -0.0028). Concerning the cytogenetics (available in 81 patients) we found no significant correlation between the expression of bcl-2 mRNA and the karyotyping. Cox regression analysis revealed the expression of bcl-2 mRNA to be independent from sex, age, white blood cell count (WBC), bone marrow cellularity and especially cytogenetics.
Expression of bcl-2 protein
AML blasts from 24 patients were analyzed for bcl-2 protein by flow-cytometry. All patients were bcl-2 + . The mean intensity of the detected bcl-2 protein expression in positive cells varied from 18 to 97 in arbitrary units.
The bcl-2 mRNA expression divided into no/low and high expression according to the results of the quantitative RT-PCR was correlated significantly with the protein results obtained by flow-cytometry (P < 0.02, data not shown), but the overlap was remarkable.
Correlation to therapy outcome and long-term prognosis
One hundred fifty-four of the 156 patients were evaluable for response. The median observation time was 29 months (range 1+-63+). One hundred four (68%) of the 154 patients achieved a CR following chemotherapy ( Table 2 ). The probability of one-, three-and five-year OS for all studied patients was 47%, 25% and 25%, respectively. Thirty-nine complete-responders (38%) relapsed after a median time of seven months (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] DFS of 40%, 26% and 26% after one, three and five years, respectively. Patients who underwent bone marrow or stem cell transplantation were censored at time of transplantation. Sixty of 93 patients (65%) with high expression of bcl-2 mRNA achieved CR, compared to a CR rate of 81% in bcl-2 weakly positive and 60% in bcl-2 negative cases ( Table 2) . Twenty-seven patients (45%) of the 60 CR patients relapsed compared to 21% of those with weak detection of bcl-2 mRNA and 40% of bcl-2 negative patients (Table 2) .
In de novo AML, 71% (10 of 14) of bcl-2 negative patients and 86% (25 of 29) of patients with weak detection of bcl-2 mRNA achieved CR compared to 48 of 74 (65%) AML patients with high expression (P = 0.0618). The probability of achieving a continuing CR in de novo AML patients and patients < 60 years was significantly lower with high expression of bcl-2 mRNA (P -0.0073 and P -0.0013, respectively). In AML patients with antecedent MDS, there was no significant correlation between the level of bcl-2 expression and CR rate (45% vs. 57% vs. 63%, not significant). Concerning all patient groups (de novo AML, AML following MDS, patients < 60 years) strong expression of bcl-2 was associated with the highest relapse and death rate compared to the patients with undetectable or weak RNA expression. Patients with low bcl-2 mRNA levels had the highest CR rate (Table 2) . In regard to OS, patients with no or low expression of bcl-2, respectively, had a significant better long-term outcome compared to patients with high expression (P = 0.028, Figure 3) . This difference was more obvious in de novo AML (P = 0.0058, Figure not shown) and patients < 60 years (P -0.0004, Figure 3 ). Similar results were found concerning the DFS of all patients (P = 0.041, Figure 4 ) and the DFS of patients < 60 years (P -0.0004, Figure 4 ).
Discussion
The product of the bcl-2 protooncogene is suggested to contribute to leukemogenesis by prolonging the life span of progenitor cells [37] . As a potent inhibitor of apoptosis, bcl-2 has a proven oncogenic potential [38] and is able to protect leukemic blasts from apoptosis induced by chemotherapy [9] . The increase of chemoresistance by upregulated bcl-2 suggests it to be directly involved in the appearance of drug resistance and contribute to an unfavorable treatment outcome [7, 9, 16, 17] . Here, we analyzed the clinical value of bcl-2 mRNA as a determinant of therapy response and prognosis. We analyzed 219 AML bone marrow (BM) samples including 119 de novo AML at presentation, 37 samples of AML following MDS, 21 samples of AML in CR and 42 AML samples in relapse. To perform quantitative measurements of bcl-2 mRNA, we developed a quantitative RT-PCR and correlated the intensity of expression to clinical outcome and long-term prognosis. Our results indicate a significantly lower probability of achieving and sustaining CR in AML patients with high bcl-2 mRNA expression, especially in de novo AML cases and patients < 60 years. Moreover, the long-term prognosis in patients with high detection levels of bcl-2 transcripts was significantly worse compared to AMLs with no or weak detection levels. The probability of one-and threeyear OS was 43% and 10% in high-expressing patients compared to 53% and 49% in AML patients with no or low expression of bcl-2, respectively (Figure 3) .
Concerning the FAB classification, our data support the recent results indicating significantly lower levels of bcl-2 mRNA expression in monocytic AMLs (M4 and M5, Table 1 ) [39] , but is in contrast to the report of Campos et al. [16] who found a significantly higher percentage of bc!-2 + cells in these FAB subtypes. However, our results confirm the general observation of higher bcl-2 expression in more immature cells [5] .
In contrast to de novo AML, high bcl-2 expression in MDS seems not to be associated with poor prognosis. Lepelley et al. [40] reported a tendency for lower response rate to chemotherapy and shorter survival in MDS cases with low bcl-2 protein expression, which was apparently due to the significantly high percentage of p53 mutations in these cases. This strong correlation of weak bcl-2 protein expression and the presence ofp53 mutations in MDS was also found in breast cancer cell lines and non-Hodgkin's lymphomas [41, 42] . However, Delia et al. [5] reported a significant increase in bcl-2 + blasts in most of the RAEB and RAEB-t cases. In our analysis, AML patients following MDS had a significantly lower level of bcl-2 expression than patients with de novo AML although the clinical outcome was generally poor in these patients.
In patients > 60 years, the bcl-2 expression was not associated with remission rate, relapse rate or survival, comparable to the results in AML with antecedent MDS. This confirms recent theories suggesting a resemblance between the biology of AML following MDS and the AML of the elderly. In these cases which are known to have more frequently multiple and complex chromosomal aberrations, bcl-2 seems not to be of relevance concerning response or prognosis. Another reason may be the age-adapted therapy approach in the elderly.
Besides the postulated involvement in drug resistance, the prognostic value of bcl-2 may be due to a correlation of bcl-2 and maturation. The bcl-2 protein expression was found to be inversely related to maturation and was high in CD34+ progenitor cells and CD34+ AML cases. [5, 16, 43] . These findings could contribute to the prognostic relevance of bcl-2 expression, since CD34+ AML cases are discussed to have an unfavorable outcome [44] . Vice versa, the poor prognosis previously associated with AML blasts expressing the CD34 antigen may in part be related to high expression of bcl-2 in these cells [43] .
Furthermore, bcl-2 and its homologue and functional agonist bcl-X\ were found to be expressed at higher levels in poor prognosis AML cases classified by karyotyping [45] . However, in our study the expression of bcl-2 mRNA did not correlate to prognostic groups defined by karyotyping (Table 1) .
In AML patients in CR, the expression of bcl-2 mRNA was significantly lower compared to de novo AML at presentation {P -0.022) or to AML cases at diagnosis of relapse (P = 0.0032, Table 1 ). Bcl-2 is expressed in normal myeloid progenitor cells, in a large fraction of myeloblasts and promyeloblasts, whereas metamyelocytes are mostly, and monocytes and neutrophils totally bcl-2 negative [5, 39] . But nevertheless, most of the detected bcl-2 mRNA expression at disease presentation may arise from the malignant blast population and contains prognostic value for the clinical outcome of AML patients.
In conclusion, from the results on bcl-2 mRNA expression in the clinical course of AML patients and its correlation to prognosis, bcl-2 mRNA may serve as a significant prognostic factor for predicting remission and long-term outcome, independent from sex, WBC, age or cytogenetics. Therefore, analysis of bcl-2 expression accompanying routine bone marrow analysis may be helpful defining high-risk patient groups for modified therapeutic strategies.
